Guideline for the Treatment of Breakthrough and the Prevention of Refractory Chemotherapy-Induced Nausea and Vomiting in Children With Cancer

Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial

(2015) Hyoung Jin Kang et al.   LANCET ONCOLOGY

Guideline for the prevention and treatment of anticipatory nausea and vomiting due to chemotherapy in pediatric cancer patients

(2014) L. Lee Dupuis et al.   PEDIATRIC BLOOD & CANCER

Olanzapine for treatment and prevention of acute chemotherapy-induced vomiting in children: A retrospective, multi-center review

(2014) Jacqueline Flank et al.   PEDIATRIC BLOOD & CANCER

Comparative effectiveness research in antineoplastic-induced nausea and vomiting control in children

(2014) Jacqueline Flank et al.   Journal of Comparative Effectiveness Research

Safety and efficacy of aprepitant for chemotherapy-induced nausea and vomiting in pediatric patients: A prospective, observational study

(2013) Megan Bodge et al.   PEDIATRIC BLOOD & CANCER

Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients

(2013) L. Lee Dupuis et al.   PEDIATRIC BLOOD & CANCER

The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy

(2013) Rudolph M. Navari et al.   SUPPORTIVE CARE IN CANCER

Emesis control by aprepitant in children and adolescents with chemotherapy

(2013) Tiene G. M. Bauters et al.   International Journal of Clinical Pharmacy

ABH Gel Is Not Absorbed From the Skin of Normal Volunteers

(2012) Thomas J. Smith et al.   JOURNAL OF PAIN AND SYMPTOM MANAGEMENT

Efficacy and safety of palonosetron as salvage treatment in the prevention of chemotherapy-induced nausea and vomiting in patients receiving low emetogenic chemotherapy (LEC)

(2012) Paul J. Hesketh et al.   SUPPORTIVE CARE IN CANCER

Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update

(2011) Ethan Basch et al.   JOURNAL OF CLINICAL ONCOLOGY

Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients

(2011) L. Lee Dupuis et al.   PEDIATRIC BLOOD & CANCER

Aprepitant Use in Children, Adolescents, and Young Adults for the Control of Chemotherapy-Induced Nausea and Vomiting (CINV)

(2010) Mi Rim Choi et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in adolescents

(2009) Jennifer R. Shiu et al.   PEDIATRIC BLOOD & CANCER

Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: Comparison between elderly and non-elderly patient response

(2008) Elena Massa et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: A randomized, double-blind, placebo-controlled study of efficacy and tolerability

(2008) Lia Gore et al.   PEDIATRIC BLOOD & CANCER

Palonosetron (Aloxi®) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy

(2008) Maurizio Musso et al.   SUPPORTIVE CARE IN CANCER

Going from evidence to recommendations

(2008) Gordon H Guyatt et al.   BMJ-British Medical Journal

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

(2008) Gordon H Guyatt et al.   BMJ-British Medical Journal